Patients were adaptively randomized to dulaglutide doses using available data on the basis of a clinical utility index ( CUI ) of glycosylated haemoglobin A1c ( HbA1c ) versus sitagliptin at 52weeks and weight , pulse rate ( PR ) and diastolic blood pressure ( DBP ) versus placebo at 26weeks .